Trial Profile

A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; SX 682 (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

14 Mar 2023 Planned initiation date (estimated date of first participant enrollment) changed from 9 Mar 2023 to 14 Apr 2023.
09 Feb 2023 Planned initiation date changed from 9 Feb 2023 to 9 Mar 2023.
09 Jan 2023 Planned initiation date changed from 9 Jan 2023 to 9 Feb 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com